Nektar Therapeutics (NASDAQ:NKTR) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, February 25th. Analysts expect Nektar Therapeutics to post earnings of ($0.72) per share for the quarter.
Shares of NKTR stock traded down $0.33 during trading hours on Tuesday, reaching $21.98. The company had a trading volume of 9,612 shares, compared to its average volume of 1,565,442. The company has a 50 day moving average of $19.85 and a 200 day moving average of $18.46. Nektar Therapeutics has a 1-year low of $13.63 and a 1-year high of $26.75. The firm has a market cap of $3.94 billion, a price-to-earnings ratio of -8.64 and a beta of 1.76.
In related news, CEO Howard W. Robin sold 150,000 shares of the business's stock in a transaction on Wednesday, February 3rd. The stock was sold at an average price of $19.72, for a total value of $2,958,000.00. Following the sale, the chief executive officer now owns 608,693 shares in the company, valued at approximately $12,003,425.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Gil M. Labrucherie sold 50,000 shares of the company's stock in a transaction dated Thursday, February 4th. The stock was sold at an average price of $19.81, for a total value of $990,500.00. The disclosure for this sale can be found here. Insiders sold 331,904 shares of company stock valued at $6,485,240 over the last 90 days. Company insiders own 2.99% of the company's stock.
A number of brokerages have recently issued reports on NKTR. Stifel Nicolaus initiated coverage on Nektar Therapeutics in a research note on Tuesday, January 5th. They set a "hold" rating and a $18.00 price objective on the stock. Benchmark lowered Nektar Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday. They noted that the move was a valuation call. Finally, SVB Leerink lifted their price target on Nektar Therapeutics from $17.00 to $20.00 and gave the company a "market perform" rating in a research note on Thursday, November 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company's stock. The stock presently has a consensus rating of "Hold" and an average price target of $29.92.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells.
Featured Article: Net Income
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Lithium Stocks That Will Power the Electric Vehicle Boom
Demand for lithium is set to increase exponentially in the next few years. In fact, according to Statista, demand for lithium may very well double to 820,000 tons in that time. Some of that demand will come from companies that are manufacturing the batteries that we use every day. For example, lithium is an essential component of the batteries that power our mobile devices.
But the real growth will come as the United States goes all-in on electric vehicles (EVs). The Biden administration recently announced plans to have the U.S. government’s fleet of over 600,000 vehicles converted to EVs.
And as you’re aware, EV stocks are in a bubble of some sort at the moment. Some of that is due to the increasing number of companies that went public last year. However, as investors are beginning to realize, not all of these companies will be the next Tesla. In fact, some of these companies may never be successful at bringing an EV to market, at least not at the scale that will be required.
The ones that do make it will need lithium and lots of it. To help you sift through the best lithium stocks to buy, we’ve put together this special presentation.
View the "7 Lithium Stocks That Will Power the Electric Vehicle Boom".